趋化因子受体4和血管内皮生长因子在肾癌中的表达及其临床意义

目的 探讨趋化因子受体4(CXCR4)和血管内皮生长因子(VEGF)在肾癌的发生、发展中的作用及临床意义.方法 采用免疫组织化学技术SP法检测CXCR4和VEGF在56例肾癌标本(包括20例伴有淋巴结转移的肾癌组织及肾周转移的淋巴结)、10例癌旁正常组织中的表达.结果 56例肾细胞癌组织中CXCR4、VEGF的表达阳性率分别为66.1%(37/56),73.2%(41/56),明显高于正常肾组织的表达阳性率20.0%(2/10)、30.0%(3/10),两者间差异有统计学意义(P＜0.05＝.肾癌组织中CXCR4和VEGF的表达呈正相关(r=0.315,P＜0.05＝,CXCR4和VEGF的表达与肾细胞癌的分期(χ2=9.520,P=0.023;χ2=9.072,P=0.027),肿瘤的侵袭转移(χ2=4.972,P=0.026;χ2=3.910,P=0.034)及微血管密度(P＜0.05＝有关,与患者的性别(χ2=0.020,P=0.887;χ2=0.001,P=0.716)、肿瘤的大小(χ2=0.003,P=0.995;χ2=0.108,P=0.990)、病理类型(χ2=1.960,P=0.900;χ2=0.112,P=0.994)无关.结论 CXCR4和VEGF在肾癌中呈高表达并且表达呈正相关,与肾癌的发展转移及预后密切相关.可以作为判断肾癌的侵袭转移及预后的重要指标,并给肾癌的治疗提供前景.

Abstract：

Objective To study the role and clinical significance of chemokine receptor-4 (CXCR4) and vascular endothelial growth factor (VEGF) in the occurrence and development of renal cell carcinoma. Methods Expression of CXCR4 and VEGF were detected by SP immunohistochemical technique in 56 cases of kidney carcinoma tissues (including 20 cases of lymph node metastasis), 10 normal tissues nearby kidney cancer. Results The positive rates of CXCR4 and VEGF were 66. 1% (37/56) and 73. 2% (41/56),which were significantly higher than those in normal tissues( 20. 0% (2/10) and 30. 0% (3/10), respectively) (P ＜ 0. 05 ＝. The expression of CXCR4 protein was significantly positively correlated with that of VEGF protein (r = 0. 315 ,P ＜ 0.05 ＝ in renal cell carcinoma. The expression of CXCR4 and VEGF was closely related to stages of tumor ( χ2 = 9. 520, P = 0. 023; χ2 = 9. 072, P = 0. 027 ), lymphatic metastasis, degree of invasion ( χ2 =4. 972, P = 0. 026; χ2 = 3.910, P = 0. 034 ), and microvessel density ( MVD) ( P ＜ 0. 05 ＝. However, they were not related to sex ( χ2 = 0. 020, P= 0. 887; χ2 = 0. 001, P = 0. 716 ), tumor size ( χ2 = 0. 003, P = 0. 995; χ2 =0. 108, P = 0. 990) and pathologic types ( χ2 = 1. 960, P = 0. 900; χ2 = 0. 112, P = 0. 994). Conclusion There is a significant positive correlation between high expressions of CXCR4 and VEGF proteins in renal cell carcinoma,the high expressions of CXCR4 and VEGF proteins may be related to the metastasis and prognosis of renal cell carcinoma,thus they could be used as important indicators in judging the metastasis prognosis of renal cell carcinoma,and offer prospects for the treatment of renal cell carcinona.

Expressions and clinical significance of chemokine receptor-4 and vascular endothelial growth factor in renal cell carcinoma

Objective To study the role and clinical significance of chemokine receptor-4 (CXCR4) and vascular endothelial growth factor (VEGF) in the occurrence and development of renal cell carcinoma. Methods Expression of CXCR4 and VEGF were detected by SP immunohistochemical technique in 56 cases of kidney carcinoma tissues (including 20 cases of lymph node metastasis), 10 normal tissues nearby kidney cancer. Results The positive rates of CXCR4 and VEGF were 66. 1% (37/56) and 73. 2% (41/56),which were significantly higher than those in normal tissues( 20. 0% (2/10) and 30. 0% (3/10), respectively) (P ＜ 0. 05 ＝. The expression of CXCR4 protein was significantly positively correlated with that of VEGF protein (r = 0. 315 ,P ＜ 0.05 ＝ in renal cell carcinoma. The expression of CXCR4 and VEGF was closely related to stages of tumor ( χ2 = 9. 520, P = 0. 023; χ2 = 9. 072, P = 0. 027 ), lymphatic metastasis, degree of invasion ( χ2 =4. 972, P = 0. 026; χ2 = 3.910, P = 0. 034 ), and microvessel density ( MVD) ( P ＜ 0. 05 ＝. However, they were not related to sex ( χ2 = 0. 020, P= 0. 887; χ2 = 0. 001, P = 0. 716 ), tumor size ( χ2 = 0. 003, P = 0. 995; χ2 =0. 108, P = 0. 990) and pathologic types ( χ2 = 1. 960, P = 0. 900; χ2 = 0. 112, P = 0. 994). Conclusion There is a significant positive correlation between high expressions of CXCR4 and VEGF proteins in renal cell carcinoma,the high expressions of CXCR4 and VEGF proteins may be related to the metastasis and prognosis of renal cell carcinoma,thus they could be used as important indicators in judging the metastasis prognosis of renal cell carcinoma,and offer prospects for the treatment of renal cell carcinona.